2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 53.585 | 63.592 | 65.535 | 62.606 | 54.375 | 53.278 | 55.203 | 68.291 | 77.376 | 62.938 |
Total Income - EUR | 55.905 | 71.487 | 65.803 | 63.482 | 54.376 | 53.433 | 63.690 | 68.341 | 77.741 | 63.137 |
Total Expenses - EUR | 44.835 | 49.460 | 58.144 | 44.811 | 39.932 | 37.357 | 37.427 | 58.384 | 60.424 | 62.434 |
Gross Profit/Loss - EUR | 11.069 | 22.027 | 7.659 | 18.672 | 14.444 | 16.075 | 26.263 | 9.957 | 17.318 | 702 |
Net Profit/Loss - EUR | 9.390 | 19.867 | 6.311 | 18.023 | 13.882 | 15.532 | 25.662 | 9.284 | 16.542 | 83 |
Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Medilens S.r.l.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 56.285 | 55.070 | 41.682 | 27.829 | 19.754 | 14.456 | 51.936 | 35.648 | 22.360 | 9.787 |
Current Assets | 8.110 | 9.223 | 19.974 | 16.770 | 30.121 | 30.207 | 17.333 | 14.641 | 37.406 | 19.805 |
Inventories | 2.410 | 1.551 | 1.577 | 4.804 | 4.277 | 3.405 | 2.418 | 6.541 | 11.529 | 12.984 |
Receivables | 3.337 | 2.051 | 2.674 | 1.546 | 1.405 | 1.322 | 2.212 | 470 | 10.632 | 1.662 |
Cash | 2.363 | 5.620 | 15.722 | 10.420 | 24.439 | 25.481 | 12.703 | 7.629 | 15.244 | 5.159 |
Shareholders Funds | 22.570 | 33.157 | 19.466 | 30.956 | 26.577 | 27.981 | 37.875 | 21.226 | 28.521 | 12.026 |
Social Capital | 112 | 112 | 111 | 109 | 107 | 105 | 103 | 101 | 101 | 101 |
Debts | 41.825 | 31.194 | 42.309 | 13.748 | 23.298 | 16.682 | 31.534 | 29.172 | 31.499 | 17.851 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4778 - 4778" | |||||||||
CAEN Financial Year |
4778
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Medilens S.r.l.